Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04233749 · ClinicalTrials.gov registry record · Phase 2
The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans
A Phase 2 study of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans, sponsored by Henry Ford Health System.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04233749: Recruiting Phase 2 study of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans, sponsored by Henry Ford Health System.
NCT04233749 is a Phase 2 study of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans that is actively recruiting participants, run by Henry Ford Health System. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04233749, a Phase 2 study of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans, is actively recruiting participants, sponsored by Henry Ford Health System.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder. Given that LPP, EDP, and melasma are all disorders of pigmentation with dermal involvement, it is possible that tranexamic acid can also reduce pigmentation in LPP and EDP as well.
Primary Outcome
Determine if there is a reduction in pigmentation in patients with LPP or EDP after administration of tranexamic acid using colorimetry.
Conditions Studied
Interventions
- DRUG Tranexamic acid tablets
Study Locations (1)
Michigan
- New Center One - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-03-17 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
What NCT04233749 shows while recruiting
NCT04233749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Lichen Planus Pigmentosus appearing as the primary indexed condition, and to 1 intervention - of which Tranexamic acid tablets is the first listed.
NCT04233749 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT04233749 about?
NCT04233749 is a clinical study titled "The Efficacy of Tranexamic Acid in the Treatment of Lichen Planus Pigmentosus and Erythema Dyschromicum Perstans". There are currently no effective treatments for lichen planus pigmentosus (LPP) and erythema dyschromicum perstans (EDP). Tranexamic acid, which may downregulate pigmentation through a reduction in plasmin, has been shown to decrease pigmentation in patients with melasma, another pigmentary disorder...
What is the current status of trial NCT04233749?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2020-03-17. Estimated completion is 2025-12-30.
What conditions does trial NCT04233749 study?
This clinical trial studies the following conditions: Lichen Planus Pigmentosus, Erythema Dyschromicum Perstans, Ashy Dermatosis of Ramirez.
What interventions are being tested in trial NCT04233749?
The interventions under investigation include: Tranexamic acid tablets (DRUG).
Who is sponsoring clinical trial NCT04233749?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04233749 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04233749's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI